Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update

Go back to Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update

Achieve Life Sciences (ACHV) Reports Q3 Loss of $0.71

November 7, 2018 4:23 PM EST

Achieve Life Sciences (NASDAQ: ACHV) reported Q3 EPS of ($0.71).

As of September 30, 2018, the company\'s cash, cash equivalents, short-term investments and restricted cash were $13.2 million. Total operating expenses for the three and nine months ended September 30, 2018 were $3.3 million and $9.1 million,... More